Streptozotocin/5-Fluorouracil (STZ/5FU) Chemotherapy in G1-G2 Pancreatic Neuroendocrine Tumors (pNETs): Single Institution Experience

#1023

Introduction: STZ is the only FDA-approved antiblastic drug for well-/moderately-differentiated NETs. To date, no clear therapeutic sequence is defined for medical treatment of advanced pNETs.

Aim(s): To evaluate STZ/5FU chemotherapy regimen in selected pNETs.

Materials and methods: Progressive and advanced G1-G2 pNETs patients were considered elegible for treatment. STZ/5FU schedule was: 500 mg/m2 for both drugs day 1-5 every six weeks. Four to six cycles were planned. The patients were considered evaluable for response once undergoing a minimum of two cycles. Response to treatment was evaluated every two cycles, according to RECIST v1.1 criteria. Toxicity was evaluated according to CTC v4.0.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author: Cingarlini S

Authors: Cingarlini S, Trentin C, Ortolani S, Grego E, D'Onofrio M,

Keywords: Streptozotocin, 5-fluorouracil, pNETs,